ANEST IWATA (6381) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
12 May, 2026Executive summary
Net sales rose 2.8% year-on-year to ¥55,909 million, driven by growth in Air Energy and Coating businesses, though both saw profit declines.
Operating profit fell 5.8% year-on-year to ¥5,563 million due to higher personnel costs, despite lower SG&A expenses.
Net profit attributable to owners surged 25.2% year-on-year to ¥5,356 million, a record high, aided by foreign exchange gains and extraordinary income from asset sales; ROE reached 11.0%.
Ordinary profit increased 8.1% year-on-year to ¥7,718 million, supported by foreign exchange gains and reduced extraordinary losses.
Comprehensive income grew 13.0% to ¥7,490 million.
Financial highlights
Total assets increased 7.9% to ¥74,641 million; net assets rose 7.4% to ¥57,542 million.
Equity ratio improved to 68.0% (+0.3 points year-on-year).
Cash and cash equivalents at year-end were ¥18,096 million, up 2.3%.
Dividend per share planned at ¥87, up ¥4 from initial forecast, with a DOE of 7.0% and payout ratio of 41.6%.
Foreign exchange gains totaled ¥467 million, up ¥446 million year-on-year.
Outlook and guidance
FY2026 revenue forecast at ¥60,000 million (+7.3% year-on-year), but operating profit expected to decline 6.5% to ¥5,200 million.
Net profit forecast to drop 26.3% to ¥3,950 million due to higher labor, logistics, and R&D costs, and absence of prior year’s extraordinary gains.
Dividend per share for FY2026 expected at ¥93, including a ¥5 commemorative dividend; share buyback program up to ¥1.5 billion to commence.
Ordinary profit for FY2026 forecast at ¥6,460 million (–16.3%).
Latest events from ANEST IWATA
- Aims for ¥100B sales by 2035 via global expansion, innovation, and new business creation.6381
Investor presentation12 May 2026 - Profits and sales fell, but financial stability and full-year guidance were maintained.6381
Q3 202610 Feb 2026 - Sales and profit fell, but FX gains and cash flow stability kept guidance unchanged.6381
Q2 202628 Nov 2025 - Q1 sales and profits declined, comprehensive income turned negative, but guidance is unchanged.6381
Q1 20268 Aug 2025 - Sales rose but profits fell on margin and forex pressures; outlook and dividend steady.6381
Q2 202413 Jun 2025 - Sales rose but profits fell on higher costs; full-year outlook maintained amid global risks.6381
Q1 202513 Jun 2025 - Sales up, profits down; FY2025 targets higher sales, lower earnings, and a dividend increase.6381
Q4 20256 Jun 2025 - Profit outlook cut as China lags and costs rise, but investment and R&D remain on track.6381
Q3 20255 Jun 2025